Concepts (114)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 18 | 2023 | 232 | 3.520 |
Why?
|
| Sleep Apnea, Central | 11 | 2022 | 13 | 3.160 |
Why?
|
| Sleep Apnea Syndromes | 4 | 2023 | 31 | 1.610 |
Why?
|
| Electric Stimulation Therapy | 7 | 2022 | 56 | 1.400 |
Why?
|
| Sleep Apnea, Obstructive | 3 | 2023 | 38 | 1.050 |
Why?
|
| Phrenic Nerve | 7 | 2020 | 22 | 1.050 |
Why?
|
| Monitoring, Ambulatory | 3 | 2009 | 26 | 0.670 |
Why?
|
| Diaphragm | 2 | 2020 | 14 | 0.630 |
Why?
|
| Respiratory Mechanics | 1 | 2014 | 16 | 0.460 |
Why?
|
| Defibrillators, Implantable | 3 | 2009 | 45 | 0.430 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 346 | 0.390 |
Why?
|
| Cardiography, Impedance | 3 | 2011 | 7 | 0.390 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2011 | 18 | 0.370 |
Why?
|
| Humans | 24 | 2023 | 26856 | 0.340 |
Why?
|
| Oxygen | 3 | 2020 | 218 | 0.310 |
Why?
|
| Treatment Outcome | 9 | 2022 | 2267 | 0.310 |
Why?
|
| Plasma Volume | 1 | 2008 | 6 | 0.310 |
Why?
|
| Monitoring, Physiologic | 1 | 2008 | 54 | 0.300 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2007 | 5 | 0.280 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2006 | 8 | 0.260 |
Why?
|
| Tetrazoles | 1 | 2006 | 8 | 0.260 |
Why?
|
| Benzimidazoles | 1 | 2006 | 29 | 0.260 |
Why?
|
| Sleep | 2 | 2023 | 100 | 0.240 |
Why?
|
| Quality of Life | 4 | 2022 | 463 | 0.230 |
Why?
|
| Continuous Positive Airway Pressure | 2 | 2020 | 13 | 0.200 |
Why?
|
| Catheterization, Peripheral | 1 | 2020 | 24 | 0.170 |
Why?
|
| Coronary Artery Disease | 1 | 2023 | 213 | 0.170 |
Why?
|
| Circadian Rhythm | 1 | 2020 | 75 | 0.170 |
Why?
|
| Hypertension | 1 | 2023 | 304 | 0.170 |
Why?
|
| Stroke Volume | 1 | 2020 | 111 | 0.170 |
Why?
|
| Hypoxia | 1 | 2020 | 85 | 0.170 |
Why?
|
| Sleep, REM | 1 | 2019 | 21 | 0.160 |
Why?
|
| Ventricular Function, Left | 1 | 2019 | 100 | 0.150 |
Why?
|
| Comorbidity | 2 | 2015 | 251 | 0.140 |
Why?
|
| Prospective Studies | 5 | 2022 | 1219 | 0.140 |
Why?
|
| Implantable Neurostimulators | 1 | 2017 | 2 | 0.140 |
Why?
|
| Masks | 1 | 2017 | 9 | 0.140 |
Why?
|
| Positive-Pressure Respiration | 1 | 2017 | 14 | 0.140 |
Why?
|
| Multicenter Studies as Topic | 1 | 2017 | 42 | 0.140 |
Why?
|
| Carbon Dioxide | 1 | 2017 | 85 | 0.130 |
Why?
|
| Risk Factors | 4 | 2015 | 2017 | 0.130 |
Why?
|
| Aged | 8 | 2020 | 5169 | 0.130 |
Why?
|
| Global Health | 1 | 2015 | 43 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 358 | 0.120 |
Why?
|
| Hemodynamics | 2 | 2008 | 220 | 0.120 |
Why?
|
| Male | 9 | 2020 | 12866 | 0.120 |
Why?
|
| Female | 10 | 2020 | 14462 | 0.120 |
Why?
|
| Equipment Design | 1 | 2014 | 211 | 0.110 |
Why?
|
| Polysomnography | 3 | 2020 | 43 | 0.110 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 981 | 0.100 |
Why?
|
| Patient Care | 1 | 2011 | 12 | 0.100 |
Why?
|
| Referral and Consultation | 1 | 2011 | 87 | 0.090 |
Why?
|
| Physician-Patient Relations | 1 | 2011 | 110 | 0.090 |
Why?
|
| Middle Aged | 6 | 2020 | 6825 | 0.090 |
Why?
|
| Blood Volume | 1 | 2010 | 8 | 0.090 |
Why?
|
| Lung | 1 | 2013 | 346 | 0.090 |
Why?
|
| Warfarin | 1 | 2010 | 94 | 0.080 |
Why?
|
| Sex Factors | 1 | 2011 | 445 | 0.080 |
Why?
|
| Time Factors | 3 | 2020 | 1564 | 0.080 |
Why?
|
| Telemetry | 1 | 2008 | 8 | 0.080 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2008 | 3 | 0.080 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2008 | 11 | 0.080 |
Why?
|
| Heart-Assist Devices | 1 | 2008 | 26 | 0.070 |
Why?
|
| Echocardiography | 1 | 2008 | 107 | 0.070 |
Why?
|
| Anticoagulants | 1 | 2010 | 293 | 0.070 |
Why?
|
| Hospitalization | 1 | 2009 | 193 | 0.070 |
Why?
|
| Decision Trees | 1 | 2007 | 7 | 0.070 |
Why?
|
| Body Weight | 1 | 2008 | 245 | 0.070 |
Why?
|
| Heart Rate | 1 | 2008 | 374 | 0.070 |
Why?
|
| Heart Failure, Systolic | 1 | 2006 | 3 | 0.070 |
Why?
|
| Death, Sudden | 1 | 2006 | 15 | 0.070 |
Why?
|
| Hyperkalemia | 1 | 2006 | 8 | 0.070 |
Why?
|
| Biphenyl Compounds | 1 | 2006 | 22 | 0.060 |
Why?
|
| Kidney Diseases | 1 | 2006 | 58 | 0.060 |
Why?
|
| Etiocholanolone | 1 | 2003 | 1 | 0.060 |
Why?
|
| Dobutamine | 1 | 2003 | 7 | 0.060 |
Why?
|
| Adult | 4 | 2022 | 7389 | 0.060 |
Why?
|
| Cardiotonic Agents | 1 | 2003 | 25 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 447 | 0.050 |
Why?
|
| Apolipoproteins C | 1 | 2003 | 4 | 0.050 |
Why?
|
| Apolipoproteins B | 1 | 2003 | 18 | 0.050 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2003 | 63 | 0.050 |
Why?
|
| Lipoproteins | 1 | 2003 | 95 | 0.050 |
Why?
|
| Pandemics | 1 | 2023 | 166 | 0.050 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2020 | 25 | 0.040 |
Why?
|
| Cheyne-Stokes Respiration | 1 | 2020 | 1 | 0.040 |
Why?
|
| Respiration | 1 | 2020 | 45 | 0.040 |
Why?
|
| Patient Safety | 1 | 2019 | 36 | 0.040 |
Why?
|
| Patients | 1 | 2019 | 17 | 0.040 |
Why?
|
| Obesity | 1 | 2003 | 647 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2010 | 860 | 0.030 |
Why?
|
| Biomarkers | 1 | 2020 | 731 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2010 | 1927 | 0.030 |
Why?
|
| Arousal | 1 | 2011 | 38 | 0.020 |
Why?
|
| Prevalence | 1 | 2013 | 469 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2011 | 187 | 0.020 |
Why?
|
| International Normalized Ratio | 1 | 2010 | 27 | 0.020 |
Why?
|
| Disease Progression | 1 | 2011 | 450 | 0.020 |
Why?
|
| Registries | 1 | 2011 | 383 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2011 | 586 | 0.020 |
Why?
|
| Prognosis | 1 | 2011 | 758 | 0.020 |
Why?
|
| Electric Impedance | 1 | 2009 | 30 | 0.020 |
Why?
|
| Acute Disease | 1 | 2009 | 156 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 400 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 588 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2010 | 391 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2011 | 917 | 0.020 |
Why?
|
| Atrial Fibrillation | 1 | 2010 | 398 | 0.020 |
Why?
|
| Apolipoprotein C-III | 1 | 2003 | 12 | 0.010 |
Why?
|
| Dogs | 1 | 2003 | 504 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2009 | 2444 | 0.010 |
Why?
|
| Protein Binding | 1 | 2003 | 631 | 0.010 |
Why?
|
| Adolescent | 1 | 2003 | 2960 | 0.010 |
Why?
|
| Animals | 1 | 2003 | 9954 | 0.010 |
Why?
|